Clinical effectiveness analysis of CT-guided percutaneous catheter-directed sclerotherapy for ovarian endometriomas

doi:10.3877/cma.j.issn.2095-5782.2022.04.009

Abstract

Abstract:

Objective

To assessed the clinical effectiveness and safety of CT-guided percutaneous catheter-directed sclerotherapy (CDS) with lauromacrogol foam for ovarian endometriomas (OEM).

Methods

Of the 51 patients who underwent CDS for OEM were retrospectively analyzed, eight cases were punctured from the anterolateral abdominal wall, while 43 cases were punctured from buttock. Subsequently, lauromacrogol foam was injected into the cyst of OEM. Cyst size, serum cancer antigen 125 (CA-125), and serum anti-Müllerian hormone (AMH) levels were compared before and after the procedure. Operational complications were reviewed.

Results

The overall disease control rate of 51 patients was 98.0%. The mean size of cysts significantly decreased from before to after 3-months and 6-months of sclerotherapy (both P < 0.001). CA125 levels declined significantly from before to after 3-months and 6-months of sclerotherapy (both P < 0.001). There was no statistically significant difference between the after 6-months and preoperative or after 3-months of sclerotherapy AMH levels (P = 0.421, P = 0.182, respectively). There were no procedure-related seriously complications.

Conclusions

CT-guided percutaneous CDS for OEM is a safe, effective alternative to surgical intervention for treatment part of large diameter (≥4 cm) OEM.

Key words: CT, Sclerotherapy, Endometriosis, Efficacy

Qiusong Liu, Xu Zhou, Junwei Lin, Hongjian Zhang, Heng Pan, Peng Guo, Mingzuo Wang, Huan Guo, Yilin Zhao. Clinical effectiveness analysis of CT-guided percutaneous catheter-directed sclerotherapy for ovarian endometriomas[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2022, 10(04): 391-395.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjrfsxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5782.2022.04.009

https://zhjrfsxdzzz.cma-cmc.com.cn/EN/Y2022/V10/I04/391

Figures/Tables 3

References 20

[1]	Llarena N C, Falcone T, Flyckt R L. Fertility Preservation in Women With Endometriosis[J]. Clin Med Insights Reprod Health, 2019, 13: 1179558119873386.
[2]	Brosens I, Gordts S, Puttemans P, et al. Pathophysiology proposed as the basis for modern management of the ovarian endometrioma[J]. Reprod Biomed Online, 2014, 28(2): 232-238.
[3]	Cohen A, Almog B, Tulandi T. Sclerotherapy in the management of ovarian endometrioma: systematic review and meta-analysis[J]. Fertil Steril, 2017, 108(1): 117-124.e5.
[4]	Galczynski K, Jozwik M, Lewkowicz D, et al. Ovarian endometrioma-a possible finding in adolescent girls and young women: a mini-review[J]. J Ovarian Res, 2019, 12(1): 104.
[5]	Hsieh CL, Shiau CS, Lo LM, et al. Effectiveness of ultrasound-guided aspiration and sclerotherapy with 95% ethanol for treatment of recurrent ovarian endometriomas[J]. Fertil Steril, 2009, 91(6): 2709-2713.
[6]	李龙, 张迪, 曾欣巧, 等. 制作1%聚桂醇泡沫硬化剂的最佳液-气比[J]. 介入放射学杂志, 2015(5): 418-421.
[7]	宋樟伟, 林玲玲, 赵雅萍, 等. 聚桂醇与无水乙醇治疗卵巢巧克力囊肿的临床疗效分析[J]. 浙江临床医学, 2017, 19(2): 251-252.
[8]	Kim ML, Cho YJ, Kim MK, et al. The efficacy of long-term maintenance therapy with a levonorgestrel-releasing intrauterine system for prevention of ovarian endometrioma recurrence[J]. Int J Gynaecol Obstet, 2016, 134(3): 256-259.
[9]	Benagiano G, Guo SW, Bianchi P, et al. Pharmacologic treatment of the ovarian endometrioma[J]. Expert Opin Pharmacother, 2016, 17(15): 2019-2031.
[10]	Grandi G, Barra F, Ferrero S, et al. Hormonal contraception in women with endometriosis: a systematic review[J]. Eur J Contracept Reprod Health Care, 2019, 24(1): 61-70.
[11]	Muzii L, Galati G, Di Tucci C, et al. Medical treatment of ovarian endometriomas: a prospective evaluation of the effect of dienogest on ovarian reserve, cyst diameter, and associated pain[J]. Gynecol Endocrinol, 2020, 36(1): 81-83.
[12]	Gordts S, Koninckx P, Brosens I. Pathogenesis of deep endometriosis[J]. Fertil Steril, 2017, 108(6): 872-885.e1.
[13]	Zakhari A, Edwards D, Ryu M, et al. Dienogest and the Risk of Endometriosis Recurrence Following Surgery: A Systematic Review and Meta-analysis[J]. J Minim Invasive Gynecol, 2020, 27(7): 1503-1510.
[14]	Huang L, Chang MY, Shiau CS, et al. Changes in anti-mullerian hormone after ultrasound guided aspiration and ethanol sclerotic therapy of ovarian cyst[J]. Taiwan J Obstet Gynecol, 2021, 60(3): 509-512.
[15]	Shin KH, Kim HH, Kwon BS, et al. Clinical usefulness of cancer antigen (CA) 125, human epididymis 4, and CA72-4 levels and risk of ovarian malignancy algorithm values for diagnosing ovarian tumors in Korean patients with and without endometriosis[J]. Ann Lab Med, 2020, 40(1): 40-47.
[16]	肖丽珍, 方锋凯, 陈开良. 超声引导下介入治疗对卵巢巧克力囊肿患者血清转录因子活化蛋白激酶B、糖类抗原125、白细胞介素-6的影响[J]. 介入放射学杂志, 2020, 29(11): 1131-1135.
[17]	Leone Roberti Maggiore U, Gupta JK, Ferrero S. Treatment of endometrioma for improving fertility[J]. Eur J Obstet Gynecol Reprod Biol, 2017, 209: 81-85.
[18]	Birch Petersen K, Hvidman HW, Forman JL, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan[J]. Hum Reprod, 2015, 30(10): 2364-2375.
[19]	Techatraisak K, Hestiantoro A, Ruey S, et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice[J]. BMC Womens Health, 2019, 19(1): 68.
[20]	Alborzi S, Zahiri Sorouri Z, Askari E, et al. The success of various endometrioma treatments in infertility: A systematic review and meta-analysis of prospective studies[J]. Reprod Med Biol, 2019, 18(4): 312-322.

参数	未婚组（39例）	已婚组（12例）	P值
年龄（岁）	20~36（27）	22~38（27）	0.647
单侧囊肿（例）	28	6	0.166
双侧囊肿（例）	11	6
术前囊肿最大径（cm）	7.58 ± 2.65	5.97 ± 1.29	0.032
术前AMH（ng/mL）	2.98 ± 1.43	2.63 ± 2.04	0.230
术前CA125（U/mL）	80.06 ± 70.46	98.30 ± 111.95	0.965

参数	未婚组（39例）	已婚组（12例）	P值
年龄（岁）	20~36（27）	22~38（27）	0.647
单侧囊肿（例）	28	6	0.166
双侧囊肿（例）	11	6
术前囊肿最大径（cm）	7.58 ± 2.65	5.97 ± 1.29	0.032
术前AMH（ng/mL）	2.98 ± 1.43	2.63 ± 2.04	0.230
术前CA125（U/mL）	80.06 ± 70.46	98.30 ± 111.95	0.965

疗效指标	术前	术后3个月	术后6个月	P值*	P值**	P值***
囊肿最大径（cm）	7.20 ± 2.48	1.47 ± 1.73	1.44 ± 1.63	< 0.001	< 0.001	0.153
CA125（U/mL）	84.35 ± 81.19	24.10 ± 23.89	22.65 ± 19.48	< 0.001	< 0.001	0.705
AMH（ng/mL）	2.90 ± 1.58	2.30 ± 1.42	2.57 ± 1.42	0.028	0.421	0.182

疗效指标	术前	术后3个月	术后6个月	P值*	P值**	P值***
囊肿最大径（cm）	7.20 ± 2.48	1.47 ± 1.73	1.44 ± 1.63	< 0.001	< 0.001	0.153
CA125（U/mL）	84.35 ± 81.19	24.10 ± 23.89	22.65 ± 19.48	< 0.001	< 0.001	0.705
AMH（ng/mL）	2.90 ± 1.58	2.30 ± 1.42	2.57 ± 1.42	0.028	0.421	0.182

Please choose a citation manager

Content to export